NovoCure Confirms Nasdaq Listing for Ordinary Shares

TL;DR

**NovoCure's shares are still trading on Nasdaq, business as usual.**

AI Summary

NovoCure Ltd. filed an 8-K on January 9, 2024, to report that its Ordinary Shares, with no par value, are registered for trading on The Nasdaq Stock Market LLC under the trading symbol NVCR. This filing, under Section 13 or 15(d) of The Securities Exchange Act of 1934, confirms the company's compliance with regulatory requirements for publicly traded companies. For investors, this matters because it reaffirms NovoCure's status as a publicly traded entity, ensuring continued liquidity and transparency for its stock on a major exchange.

Why It Matters

This filing confirms NovoCure's continued listing on Nasdaq, which is crucial for maintaining investor confidence and ensuring the liquidity of its shares.

Risk Assessment

Risk Level: low — This filing is a routine regulatory update and does not indicate any new financial or operational risks for the company.

Analyst Insight

This filing is a standard regulatory update, so a smart investor would simply note the confirmation of listing and continue to monitor for more substantive news regarding the company's operations or financial performance.

Key Players & Entities

• NovoCure Ltd. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where NovoCure's shares are registered
• NVCR (other) — NovoCure's trading symbol

FAQ

Filing Documents

• nvcr-20240109.htm (8-K) — 24KB
• tridentlpipr.htm (EX-99.1) — 16KB
• 0001645113-24-000004.txt ( ) — 170KB
• nvcr-20240109.xsd (EX-101.SCH) — 2KB
• nvcr-20240109_lab.xml (EX-101.LAB) — 23KB
• nvcr-20240109_pre.xml (EX-101.PRE) — 12KB
• nvcr-20240109_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 9, 2024, the Company issued a press release announcing that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio (formerly known as Optune) concurrent with radiation therapy and temozolomide (TMZ) for the treatment of patients with newly diagnosed glioblastoma (GBM). A copy of the press release is attached hereto as Exhibit 99.1. The information contained in item 7.01 of this Current Report shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated January 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: January 9, 2024 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR